News for Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics (ALLO) revealed promising results from its Phase 1 TRAVERSE study at the 2025 ASCO Annual Meeting. This study focused on the investigation

Allogene Therapeutics' (ALLO) ALLO-316 shows a 31% response rate in advanced renal cell carcinoma with high CD70 expression. Four out of five patients m

Explore Allogene's innovative CAR-T therapies targeting cancer & autoimmune diseases. ASCO updates on ALLO-316 could validate its platform. Click here to read.

Allogene Therapeutics continues to advance its pipeline, with notable progress in key clinical trials and upcoming data readouts. Click to read why ALLO is a Buy.

SOUTH SAN FRANCISCO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. ( ALLO), a clinical-stage biotechnology company pioneering the devel

**media[635282]**

SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering th

**media[634794]**

Allogene Therapeutics (ALLO) saw a notable revision in its price target from Citigroup. On May 15, 2025, analyst Samantha Semenkow adjusted the price target for

Citi has adjusted its price target for Allogene Therapeutics (ALLO), reducing it from $8 to $4 while maintaining a Buy rating. This adjustment comes in light of

Allogene Therapeutics (NASDAQ: ALLO) stock dips 17% after trial delay and downgrade to Market Perform. Read more here.

On May 14, 2025, Truist Securities, a prominent financial analysis firm, adjusted its price target for Allogene Therapeutics (ALLO), a biotechnology company. An

On May 14, 2025, RBC Capital, represented by analyst Luca Issi, reiterated its "Outperform" rating for Allogene Therapeutics (ALLO). The investment banking firm

On May 14, 2025, Oppenheimer analyst Matthew Biegler announced a revision in the price target for Allogene Therapeutics (ALLO). The price target has been lowere

On May 14, 2025, Baird analyst Jack Allen made a significant update regarding Allogene Therapeutics (ALLO). The analyst has maintained the company's current rat

Truist has revised its price target for Allogene Therapeutics (ALLO), reducing it from $14 to $10 while maintaining a Buy rating. These changes follow the compa

Oppenheimer has revised its price target for Allogene Therapeutics (ALLO), lowering it from $10 to $9 while maintaining an Outperform rating on the stock. This

The price target for Allogene Therapeutics (ALLO) has been revised downward by Baird analyst Jack Allen, moving from $12 to $9. Despite this adjustment, Allen m

The market is getting tough these days with increasing interest rates, tense world politics, and inconsistent economic conditions, and investors are constantly looking for opportunities.